New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications including ocrelizumab, rituximab, and fingolimod but not others.
Conozca como pacientes con Esclerosis Múltiple pueden generar anticuerpos contra la Covid diariodigital.com.do - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from diariodigital.com.do Daily Mail and Mail on Sunday newspapers.
Estudio refuerza el uso seguro y efectivo de Cladribina Comprimidos para pacientes con Esclerosis Múltiple - Spanish Version newsinamerica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsinamerica.com Daily Mail and Mail on Sunday newspapers.
Merck
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
Monday, April 26, 2021 9:37PM IST (4:07PM GMT)
Darmstadt, Germany:
New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies from vaccines
Independent study from Israel showed MAVENCLAD-treated patients receiving COVID-19 vaccine were able to mount antibody response similar to that of healthy subjects
Updated safety data show MAVENCLAD-treated patients with confirmed or suspected COVID-19 continue to have a disease course similar to the general population
Not intended for UK and U.S. based media
EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.